SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amid increased competition in the weight loss market, with Amazon Pharmacy now offering Novo Nordisk's Wegovy, a GLP-1 drug not available on HIMS's platform, compounded by a Bank of America downgrade citing concerns over 2026 margins. This has fueled widespread bearish sentiment and predictions of further stock declines, though some investors view it as an oversold opportunity, highlighting the company's long-term growth strategy across various healthcare verticals and international expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is a trending topic as significant share grants to CEO Michael Weiss have sparked intense debate among investors, leading to accusations of greed while also prompting discussions of potential short manipulation. The community remains focused on Briumvi's strong market performance, recent competitor setbacks, and high anticipation for strategic updates or acquisition speculation heading into the J.P. Morgan Healthcare Conference.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc. is witnessing extreme trading activity, primarily driven by a substantial special cash dividend and strong speculation of a short squeeze. The community is intensely focused on the company's evolving strategy to include blockchain-based assets and its leadership's track record of corporate turnarounds. This has ignited both fervent bullish sentiment and significant skepticism regarding the sustainability of its rapid price movement.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending following a significant agreement with Meta Platforms to develop a 1.2 GW nuclear energy campus for AI data centers in Ohio, which investors are hailing as a major validation for its advanced reactor technology. The community is actively discussing the long-term potential of nuclear power to meet AI's massive energy demands and speculating on impending DOE plutonium awards, while skeptics highlight the company's zero revenue and distant timelines for operational power production.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending amid significant price volatility, as recent strong earnings were followed by a sharp decline, attributed by some to institutional profit-taking and an analyst downgrade. The community is actively discussing heightened competition in the observability sector, particularly from a rival's rumored acquisition, while also seeing the current levels as a compelling buying opportunity given Datadog's robust AI integrations and sticky revenue. Adding to the buzz, there are circulating rumors about Datadog itself exploring a potential takeover bid for GitLab.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending following a substantial institutional capital raise, which the community is interpreting as a strong vote of confidence given its premium pricing and long-term warrants. This move fuels anticipation for significant growth and potential acquisitions within the rapidly expanding defense and drone technology sector. Investors are keenly awaiting further insights from the upcoming investor conference and details on rumored major contracts.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

ATOM is trending as its community actively discusses a proposed tokenomics redesign intended to transition from inflationary rewards to a revenue-based model, aiming to bolster its value accrual. Many investors are attracted by the consistently high 15%+ staking APY and express long-term belief in Cosmos' "Internet of Blockchains" vision. However, others remain cautious, pointing to historical price struggles despite these incentives.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amid intense buyout speculation, fueled by strong financial performance and anticipation of critical updates on its AUR200 pipeline, particularly regarding planned Phase 2 indications. Community discussion highlights growing frustration with management's perceived lack of transparency, even as the company's strong fundamentals and recent patent lawsuit consolidation position it as a compelling acquisition target in a dynamic biotech M&A environment.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending after news of CEO Ryan Cohen's performance-based compensation, which ties his pay to ambitious market capitalization and EBITDA targets, alongside ongoing strategic store closures. This has ignited debate among investors, with bulls seeing it as a strong alignment of interests signaling significant future growth, while skeptics view the targets as unrealistic given past stock performance and the company's current trajectory.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS CRYPTO) is generating significant community excitement due to its recently announced token burn proposal, aiming for deflationary tokenomics, and a new roadmap for multi-chain and AI-powered liquid staking infrastructure. Despite a recent delisting, strong bullish sentiment persists, fueled by its perceived low market cap, continued presence on major exchanges, and anticipation of substantial upside as a liquid staking protocol.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 EPS Estimates for Assertio Increased by HC Wainwright

Assertio Holdings, Inc. (NASDAQ:ASRT - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for Assertio in a note issued to investors on Monday...

Assertio (NASDAQ:ASRT) Raised to Strong-Buy at Zacks Research

Zacks Research raised shares of Assertio from a "hold" rating to a "strong-buy" rating in a research report on Tuesday...

Assertio (NASDAQ:ASRT) Sees Strong Trading Volume - Should You Buy?

Assertio (NASDAQ:ASRT) Sees Large Volume Increase - What's Next...

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

Assertio Holdings, Inc. (Assertio or the Company) (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation (the Certificate of Amendment) on...

Assertio (NASDAQ:ASRT) Rating Increased to Buy at Wall Street Zen

Wall Street Zen raised Assertio to a "buy" rating in a research note on Saturday...

Assertio (NASDAQ:ASRT) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Assertio (NASDAQ:ASRT - Get Free Report) issued its quarterly earnings results on Monday. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of...

Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates

Assertio (ASRT) delivered earnings and revenue surprises of +237.50% and +83.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Assertio Reports Third Quarter 2025 Financial Results

Assertio Holdings, Inc. (Assertio or the Company) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients...

Earnings Outlook For Assertio Holdings

Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3

Xeris Biopharma (XERS) delivered earnings and revenue surprises of -100.00% and +0.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

ASRT
Assertio Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ASRT News

ASRTAssertio Holdings Inc